CRISPR Therapeutics AG
CRSP
株式のランク
#3543
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
株価
$50.26
最終同期: 2026-10-20
時価総額
$4.86B
変化（1日）
0.43%
変化（1年）
-30.51%
国
CH
取引 CRISPR Therapeutics AG (CRSP)
カテゴリー
Healthcare
CRISPR Therapeutics AG（CRSP）のP/E比率
October 2026 時点のP/E比率 TTM -10.55
CRISPR Therapeutics AG の最新の財務報告および株価によると、現在の P/E (TTM) は -10.55 です。2023 年末時点での P/E は -32.28 でした。
CRISPR Therapeutics AG の P/E 比率の履歴（2014 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -10.55 | 16.32% |
| 2024 | -9.07 | -71.92% |
| 2023 | -32.28 | 564.18% |
| 2022 | -4.86 | -131.90% |
| 2021 | 15.24 | -152.65% |
| 2020 | -28.94 | -158.41% |
| 2019 | 49.55 | -696.60% |
| 2018 | -8.31 | -39.51% |
| 2017 | -13.73 | 28.29% |
| 2016 | -10.70 | -33.03% |
| 2015 | -15.98 | -73.67% |
| 2014 | -60.71 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -372.80% |
US
|
|
| -28.36 | 168.79% |
US
|
|
| -24.57 | 132.85% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -387.48% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。